Banner background image Banner background image

MANY PATIENTS WITH
ASCVD STRUGGLE
TO
ACHIEVE LDL-C
TARGET17-19

50%_graphic

Non-adherence may be a reason why your patients continue to have elevated LDL-C—increasing their CVD risk.

The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.

80%_graphic
1-3_graphic 1-3_graphic

*From an analysis of a large IQVIA open claims dataset of patients (N=72,001) between September 2020 and January 2023.

†In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAb (N=13,151) between January 1, 2016 and June 30, 2016 who were followed for a minimum of 6 months following their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.

mAb, monoclonal antibody.

  • PREFER
    FEWER
    INJECTIONS

  • STRUGGLE
    TO TAKE
    MEDICATIONS

  • WORRY
    ABOUT
    COST

Tony

Patients like Tony may
need something more, yet

PREFER FEWER INJECTIONS

Tony

Patients like Tony may
need something more, yet

PREFER FEWER INJECTIONS

• Find frequent injections a hassle

• Dislike the idea of giving themselves a shot

• Persistently elevated LDL-C

• Find frequent injections a hassle

• Dislike the idea of giving themselves a shot

• Persistently elevated LDL-C

Age: 65

Insurance: Traditional
Medicare + Supplemental

LDL-C level:

Baseline: 180 mg/dL

Current: 120 mg/dL

Current LDL-C treatment:

Atorvastatin 80 mg
(increased from 40 mg
1 month ago)

Medical history:

  • • CV events: NSTEMI and PCI 3 months ago

  • • Additional health conditions: Hypertension, metabolic syndrome, osteoarthritis

tony's LDL-C reduction since his CV event

OFFERS PATIENTS THE CHOICE OF ONLY 2 INJECTIONS A YEAR‡ WITH LEQVIO1

• HCP-administered, eliminating need for self injection1

• 2 doses of LEQVIO* vs 12-26 self injections of PCSK9 mAbs per year1,14 §

‡After 2 initial doses and taken with statin therapy.1

§This is not a complete list of all the available treatments for patients with primary hyperlipidemia who have elevated LDL-C. The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety.

SEE HOW LEQVIO DOSING CAN
HELP PATIENTS LIKE TONY

TWICE-YEARLY MAINTENANCE DOSING arrow
Robert

Patients like Robert may
need something more, yet

STRUGGLE TO TAKE
THEIR MEDICATIONS
AS PRESCRIBED

Robert

Patients like Robert may need something more, yet

STRUGGLE TO TAKE THEIR MEDICATIONS AS PRESCRIBED

• Don't want to take another pill

• Reluctant to add to at-home treatment burden

• Persistently elevated LDL-C

• Don't want to take another pill

• Reluctant to add to at-home treatment burden

• Persistently elevated LDL-C

Age: 55

Insurance: Commercial

LDL-C level:

Baseline: 160 mg/dL

Current: 105 mg/dL

Current LDL-C treatment:

Rosuvastatin 40 mg
(increased from 20 mg
8 months ago)

Medical history:

  • • CV events: Unstable angina 2 years ago due to CAD

  • • Additional health conditions: Hypertension, diabetes

Robert's LDL-C reduction since his CV event

LEQVIO® IS HCP-ADMINISTERED, SO
YOU KNOW YOUR PATIENTS GET
THEIR DOSE1

• HCP-administered, requiring less additional at-home efforts of patients1

• No added therapies to take or inject at home1

CAD, coronary artery disease; CV, cardiovascular.

SEE HOW LEQVIO DOSING CAN
HELP PATIENTS LIKE ROBERT

HCP-ADMINISTERED DOSING arrow
Carla

Patients like Carla may
need something more, yet

WORRY ABOUT THE
COST OF ANOTHER
MEDICATION

Carla

Patients like Carla may need something more, yet

WORRY ABOUT THE COST OF ANOTHER MEDICATION

• Already paying for multiple therapies

• Retired and relies on a fixed income

• Persistently elevated LDL-C

• Already paying for multiple therapies

• Retired and relies on a fixed income

• Persistently elevated LDL-C

Age: 70

Insurance: Traditional
Medicare
+ Supplemental

LDL-C level:

Baseline: 200 mg/dL

Current: 120 mg/dL

Current LDL-C treatment:

Pravastatin 40 mg + ezetimibe 10 mg (has been modifying statin therapy due to muscle aches)

Medical history:

  • • CV events: STEMI 1 year ago, PAD

  • • Additional health conditions: Hypertension, osteoporosis, atrial fibrillation

carla's LDL-C reduction since his CV event

TWICE-YEARLY‡ LEQVIO® IS AFFORDABLE FOR MOST PATIENTS.1

• 80% of Medicare patients have supplemental plans and pay as little as $04

• 65% of Commercial & Medicare patients† may pay as little as $04§

• Not subject to the Medicare Part D donut hole4

‡After 2 initial doses and taken with statin therapy.1

§Includes all insurance types: Traditional Medicare, Medicare Advantage, and Commercial plans. Based on data up to July 2023.

PAD, peripheral artery disease; STEMI, ST-elevation myocardial infarction.

SEE HOW LEQVIO IS AFFORDABLE
FOR MOST PATIENTS

BROAD INSURANCE COVERAGE arrow

LOOKING FOR MORE
INFORMATION FOR YOUR
PATIENTS?

THERE'S MORE TO
KNOW ABOUT LEQVIO

See what LEQVIO can do for patients like yours

STUDY CLINICAL DATA arrow

ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery
disease; CV, cardiovascular; LDL-C, low-density
lipoprotein cholesterol;
mAb, monoclonal antibody; MI, myocardial infarction; PAD, peripheral
arterial disease; PCI,
percutaneous coronary intervention; PCSK9,
proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation
myocardial infarction.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND IMPORTANT SAFETY
INFORMATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Integrated Summary of Efficacy. Novartis Pharmaceuticals Corp. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.